Etrasimod UC trial hints at early vindication of Pfizer's Arena buy

24 March 2022
pfizer_black_new_large

Pfizer (NYSE: PFE) has announced positive top-line results from a Phase III study of etrasimod in moderately to severely active ulcerative colitis (UC).

Etrasimod is an investigational, oral, once-a-day, selective sphingosine 1-phosphate receptor modulator that the US pharma giant picked up in its $6.7 billion buy of Arena Pharmaceuticals, announced only in December.

"Etrasimod, if approved, could be a potential breakthrough option"In the study, etrasimod patients achieved statistically-significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical